Advanced Malignant Solid Neoplasm — Expanded Access Programs
Overview
Right2Hope maintains a directory of 55 expanded access programs, clinical trials, and compassionate use pathways listed for Advanced Malignant Solid Neoplasm. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with advanced malignant solid neoplasm programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 38 programs are currently active or recruiting, with the remaining 17 in other lifecycle stages. Sponsors actively running programs in this area include National Cancer Institute (NCI), M.D. Anderson Cancer Center, OHSU Knight Cancer Institute, Jonsson Comprehensive Cancer Center, Mayo Clinic, and others.
By recruiting status
Snapshot of where every Advanced Malignant Solid Neoplasm program currently sits in its lifecycle.
- Active / Recruiting38
- Inactive17
Top sponsors
Organisations running the most Advanced Malignant Solid Neoplasm programs in the directory.
- National Cancer Institute (NCI)42 programs
- M.D. Anderson Cancer Center4 programs
- OHSU Knight Cancer Institute3 programs
- Jonsson Comprehensive Cancer Center1 program
- Mayo Clinic1 program
- Northwestern University1 program
- Roswell Park Cancer Institute1 program
- Tianhong Li1 program
- Yuanquan Yang1 program
Advanced Malignant Solid Neoplasm programs (55)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Phase 2 Study of Cediranib and Olaparib for Advanced Solid Tumors — National Cancer Institute (NCI)
- Study on Erdafitinib for Treating Children and Young Adults with Advanced Cancers with FGFR Mutations — National Cancer Institute (NCI)
- Study on Gene-Modified T Cells With or Without Decitabine for Treating Advanced Cancers with NY-ESO-1 — Roswell Park Cancer Institute
- Study on Larotrectinib for Treating Children and Young Adults with Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with NTRK Fusions — National Cancer Institute (NCI)
- Study on Morning Versus Afternoon Immunotherapy for Treating Advanced or Metastatic Solid Tumors — OHSU Knight Cancer Institute
- Study on Olaparib for Treating Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations — National Cancer Institute (NCI)
- Study on Pembrolizumab for Treating Rare Tumors That Cannot Be Surgically Removed or Have Spread — M.D. Anderson Cancer Center
- Personalized Antibody-Drug Conjugate Therapy for Advanced or Metastatic Solid Tumors Based on RNA and Protein Testing — National Cancer Institute (NCI)
- Study on Genetic Testing-Directed Targeted Therapy for Advanced Solid Tumors, Lymphomas, or Multiple Myeloma — National Cancer Institute (NCI)
- Study on Ado-Trastuzumab Emtansine for Cancers with HER2 Genetic Changes — National Cancer Institute (NCI)
- Study on Afatinib for Cancers with HER2 Genetic Changes (MATCH-Subprotocol B) — National Cancer Institute (NCI)
- Testing Afatinib for Treating Cancers with EGFR Genetic Changes — National Cancer Institute (NCI)
- Study on AZD1775 for Treating Cancers with BRCA Genetic Changes — National Cancer Institute (NCI)
- Study on AZD9291 for Treating Cancers with EGFR Genetic Changes — National Cancer Institute (NCI)
- Study on BVD-523FB (Ulixertinib) for Cancers with Specific Genetic Changes — National Cancer Institute (NCI)
- Study on Copanlisib for Treating Cancers with PIK3CA Mutations — National Cancer Institute (NCI)
- Study on Copanlisib for Treating Cancers with PTEN Gene Changes — National Cancer Institute (NCI)
- Study on Crizotinib for Cancers with ROS1 Genetic Changes (MATCH-Subprotocol G) — National Cancer Institute (NCI)
- Study on Crizotinib for Treating Cancers with MET Exon 14 Deletion Genetic Changes — National Cancer Institute (NCI)
- Study on GDC-0032 (Taselisib) for Treating Cancers with PIK3CA Genetic Changes — National Cancer Institute (NCI)
- Study on Vismodegib for Treating Cancers with Specific Genetic Mutations — National Cancer Institute (NCI)
- Study on GSK2636771 for Treating Cancers with PTEN Genetic Changes — National Cancer Institute (NCI)
- Testing GSK2636771 for Cancers with PTEN Loss of Expression — National Cancer Institute (NCI)
- Study on Ipatasertib for Treating Cancers with AKT Genetic Changes — National Cancer Institute (NCI)
- Study on Erdafitinib for Treating Cancers with FGFR Gene Amplifications — National Cancer Institute (NCI)
- Study on LOXO-101 for Treating Cancers with NTRK Genetic Changes — National Cancer Institute (NCI)
- Study on MLN0128 (TAK-228) for Cancers with mTOR Genetic Changes — National Cancer Institute (NCI)
- Study on MLN0128 (TAK-228) for Cancers with TSC1 or TSC2 Genetic Changes — National Cancer Institute (NCI)
- Study on Palbociclib as a Targeted Treatment for Cancers with CCND1, 2, or 3 Amplification — National Cancer Institute (NCI)
- Study on Palbociclib for Treating Cancers with CDK4 or CDK6 Gene Changes — National Cancer Institute (NCI)
- Study on Sunitinib for Treating Cancers with cKIT Genetic Changes — National Cancer Institute (NCI)
- Study on Adding Copanlisib to Usual Immunotherapy for Advanced Solid Cancers with PIK3CA and PTEN Gene Changes — National Cancer Institute (NCI)
- Testing Trametinib and Dabrafenib for Cancers with BRAF Genetic Changes — National Cancer Institute (NCI)
- Study on Trametinib for Treating Cancers with BRAF Genetic Changes — National Cancer Institute (NCI)
- Study on Trametinib for Cancers with GNAQ or GNA11 Genetic Changes — National Cancer Institute (NCI)
- Testing Trametinib for Cancers with NF1 Genetic Changes (MATCH-Subprotocol S1) — National Cancer Institute (NCI)
- Study on VS-6063 (Defactinib) for Cancers with NF2 Genetic Changes — National Cancer Institute (NCI)
- Study on Whether Cancers with Specific Mutations Respond Better to the Drug Telaglenastat Hydrochloride (BeGIN Study) — National Cancer Institute (NCI)
- Study on Cancer Vaccine Labvax 3(22)-23 and GM-CSF Alone or with Pembrolizumab for Treating Advanced Adenocarcinoma — Tianhong Li
- Precision Medicine Approach for Treating Advanced Sarcoma, Prostate, Breast, Ovarian, or Pancreatic Cancer — OHSU Knight Cancer Institute
- Study on Anti-CTLA4-NF mAb, Nivolumab, and Targeted Radiation Therapy for Treating Metastatic Solid Tumors — M.D. Anderson Cancer Center
- At-Home Cancer Treatment Compared to In-Clinic Treatment for Patients with Advanced Cancer — Mayo Clinic
- Study on Axatilimab, Retifanlimab, and Paclitaxel for Treating Advanced or Metastatic Solid Tumors — OHSU Knight Cancer Institute
- Study on CPI-613 (Devimistat) with Hydroxychloroquine and 5-Fluorouracil or Gemcitabine for Treating Advanced Solid Tumors — Northwestern University
- Study on Ensartinib for Treating Relapsed or Hard-to-Treat Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Changes in Children and Young Adults — National Cancer Institute (NCI)
- Study on Niraparib, Temozolomide, and Atezolizumab for Treating Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer — Jonsson Comprehensive Cancer Center
- Phase I/II Study of NBTXR3 with Radiation and Immunotherapy for Advanced Solid Tumors — M.D. Anderson Cancer Center
- Study on Plinabulin with Radiation and Immunotherapy for Advanced Cancers After PD-1 or PD-L1 Treatment — M.D. Anderson Cancer Center
- Study on Siltuximab to Prevent Severe Side Effects During Immune Therapy Restart in Patients with Advanced Cancer — Yuanquan Yang
- Study on Targeted Therapy Guided by Genetic Testing for Patients with Advanced Solid Tumors — National Cancer Institute (NCI)
- Study on Genetic Testing-Directed Targeted Therapy for Children with Relapsed or Hard-to-Treat Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders — National Cancer Institute (NCI)
- Testing a New Drug Combination, Entinostat and ZEN003694, for Advanced and Hard-to-Treat Cancers — National Cancer Institute (NCI)
- Study on the Safety and Effectiveness of Combining Temozolomide and M1774 for Treating Advanced Cancer — National Cancer Institute (NCI)
- Testing the Combination of Anti-Cancer Drugs ZEN-3694 and Talazoparib in Patients with Advanced Solid Tumors (The ComBET Trial) — National Cancer Institute (NCI)
- Study on Using AMG 510 (Sotorasib) and Panitumumab for Treating KRAS G12C Mutant Solid Tumor Cancers — National Cancer Institute (NCI)
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Advanced Malignant Solid Neoplasm to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.